Abstract
Purpose of Review: Immunotherapy is emerging as an effective treatment option for metastatic triple-negative breast cancer. In this review, we summarize clinical data of immunotherapy in triple-negative breast cancer and comment on future directions in the field. Recent Findings: IMpassion130 was a phase III trial that demonstrated progression-free survival benefit, and potentially overall survival benefit, of first-line chemotherapy (nab-paclitaxel) plus anti-programmed death ligand 1 (PD-L1) atezolizumab, among PD-L1-positive metastatic triple-negative breast cancers. Studies are ongoing to evaluate other combination therapies with immune checkpoint blockade in TNBC, and to evaluate efficacy in PD-L1-negative tumors and in later lines of therapy. Summary: Immunotherapy is now a standard option in the treatment of triple-negative breast cancer. Ongoing trials may expand the degree of clinical benefit. Further work is ongoing to identify novel predictive biomarkers, which in the future may enable a personalized approach of combination immunotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 259-271 |
Number of pages | 13 |
Journal | Current Breast Cancer Reports |
Volume | 11 |
Issue number | 4 |
DOIs | |
State | Published - Dec 1 2019 |
Externally published | Yes |
Keywords
- Breast cancer
- IMpassion130
- Immune checkpoint blockade
- Immunotherapy
- PD-L1
- Triple-negative
ASJC Scopus subject areas
- Oncology